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Abstract
Sudden death is a major cause of mortality in patients with ventricular dysfunction. The
highest risk occurs among patients with less severe functional impairment. Current methods
of risk stratification are inadequate, and a rational therapy for prevention of sudden death is
not available. The implantable cardioverter-defibrillator (ICD) has proven to be more effective
than drugs in reducing sudden-death risk in some subsets of patients. Empiric ICD therapy,
targeting the general population with mild to moderate heart failure, will maximize the impact
of such a strategy to prevent sudden death and improve long-term survival.
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Introduction
The major causes of death in patients with congestive
heart failure are sudden death and death from progressive
pump failure [1]. Mortality remains unacceptably high
despite recent pharmacological advancements in treat-
ment, with sudden, ‘unexpected’ death occurring in up to
40–70% of patients [2,3]. Although the total mortality
among patients with mild heart failure is low, the relative
proportion of patients dying suddenly is significant
(50–70%) [2,3]. The relative proportion of sudden death in
patients with more advanced heart failure amounts to less
than 30% of all causes of death. The risk is still substantial,
however, given the annual mortality of 40–60% in
advanced heart failure [2,4] (Figure 1). The major cause of
death in patients with severe congestive heart failure
(class III and IV) is from progressive myocardial dysfunc-
tion and hemodynamic deterioration. The absolute inci-
dence of sudden death, however, remains comparable
with that of functional class II patients, at approximately
30%. Sudden death tends to occur early in the course of
heart failure, and probably results from ventricular tachy-
cardia or ventricular fibrillation [5]. Although severe brady-
cardia or electromechanical dissociation may be more
prevalent in patients with advanced heart failure [6], highhttp://cvm.controlled-trials.com/content/1/2/098
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risk for developing life-threatening sustained ventricular
arrhythmias persists. An effective strategy for reducing
that risk would prevent sudden death and would save
many lives throughout the various stages of heart failure.
The causes of sudden death in heart failure are complex
and poorly understood. A rational therapeutic strategy
based on physiologic mechanisms is not available at this
time. Recommendations for prevention of sudden death in
patients with left ventricular dysfunction have evolved
largely from the results of clinical trials [4,7]. Patient popu-
lations have, however, been highly diverse among these
different studies, and formulating a consensus on a man-
agement strategy has therefore been difficult. Although
several clinical variables have been associated with an
increased cardiac mortality in patients with heart failure
[8,9], major limitations remain in identifying the individual
at highest risk of sudden death.
Risk stratification for sudden death using non-invasive
methods or programmed stimulation is inadequate and, at
best, limited to patients with coronary artery disease and
non-sustained ventricular arrhythmia [10–12]. Importantly,
preliminary analysis of outcomes in this subset of patients
who participated in the Multicenter Unsustained Tachycar-
dia Trial (MUSTT) and the Multicenter Automatic Defibrilla-
tor Implantation Trial (MADIT) suggests persistent high
risk, even in those patients without inducible ventricular
tachycardia. Moreover, ventricular programmed stimulation
has proven to be of no value in patients with non-ischemic
cardiomyopathy [13]. Prevention of sudden death in
patients with left ventricular dysfunction should thus be
based on a logical strategy that optimizes effective phar-
macologic and non-pharmacologic therapies.
Pharmacologic strategy
The efficacy of angiotension-converting enzyme (ACE)
inhibitors in decreasing overall mortality has been well estab-
lished in populations with various degrees of myocardial sys-
tolic impairment. However, the impact of ACE inhibitors on
sudden death rate is probably minimal [1,14,15].
Most trials using anti-arrhythmic drugs have resulted in
worsening outcomes in the drug treatment arms [16],
especially in patients with left ventricular dysfunction [17].
The possible exception to this rule is amiodarone, which
does not appear to have an adverse effect on either sur-
vival or heart failure. In the Congestive Heart Failure–Sur-
vival Trial of Antiarrhythmic Therapy (CHF-STAT),
amiodarone did not reduce the incidence of sudden death
or prolong survival [18]. The Argentinean GESICA trial did
show a reduction of total mortality with amiodarone com-
pared with placebo. The relative risk reduction of sudden
death was, however, insignificant [3]. Other studies such
as EMIAT [19] and CAMIAT [20] focused on patients with
ischemic heart disease and prior myocardial infarction.
These results suggested amiodarone may reduce arrhyth-
mic death, but failed to improve survival. The conflicting
outcomes of the studies evaluating amiodarone suggest
that the protective beta-blocking effects of the drug may
be offset by its pro-arrhythmia properties. The only drug
class that convincingly reduces total mortality as well as
the risk of sudden death has been beta-blockers. Relative
reductions of cardiac death and sudden death in some
trials ranged from 30 to 50%, and may involve mecha-
nisms related to anti-ischemic, anti-fibrillatory effects of
beta-blockade, neuro-endocrine deactivation or ventricular
remodeling [21,22]. Previous studies involving high-risk
patients, however, had consistently showed low rates of
beta-blocker use (<50%) [11,12,23,24]. The utility of
beta-blockers may be limited by bradyarrhythmias or wors-
ening heart failure in patient populations with heart failure.
Non-pharmacologic strategy
Non-pharmacological therapy has proven more effective in
improving survival and reducing sudden death risk. The
utility of the implantable defibrillators in ‘secondary preven-
tion’ has been well established in patients resuscitated
from cardiac arrest or syncopal ventricular tachycardia
[23,24]. Those patients with highest risk appear to benefit
most from ICD therapy [25]. Importantly, the effectiveness
of ICDs in primary prevention has also been established in
the subgroup of patients with coronary artery disease and
non-sustained ventricular tachycardia. MADIT was the first
study to evaluate the prophylactic use of ICDs in patients
with prior myocardial infarction, low ejection fraction, and
inducible but non-suppressible ventricular arrhythmias.
The use of ICDs is associated with a significant survival
benefit compared with ‘conventional’ anti-arrhythmic drug
therapy (mostly amiodarone) [11]. MADIT has been criti-
cized for its small sample size and the low rate of beta-
blocker use in patients on ‘conventional’ therapy (5%)
compared with the ICD arm (27%). However, this differ-
ence alone cannot mitigate the magnitude of mortality
reduction (54%) observed in the defibrillator group.
Figure 1
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The randomized, controlled MUSTT evaluated the utility of
electrophysiologically guided therapy to reduce the risk of
sudden death [12]. The study included a larger patient
population, but similar to that of the MADIT, and had a
higher rate of beta-blockers and ACE inhibitor use among
patients. MUSTT demonstrated that, in this relatively
asymptomatic population, inducible sustained arrhythmia
is associated with a substantial risk of dying suddenly, and
therapy guided by electrophysiologic testing resulted in a
significant reduction of sudden death. This survival benefit
was, however, solely due to the use of defibrillators.
Among patients who received defibrillators, there was no
difference in sudden death rate based on beta-blocker
use. It is also noteworthy that the 2-year mortality rate in
patients who received defibrillators was similar in both
MADIT and MUSTT, even though the rate of beta-blocker
use in MUSTT was twice that in MADIT. These data
confirm that the benefit of ICD therapy is independent of
the beneficial effects of beta-blockers.
Other ongoing trials, such as the Defibrillators in Non-
Ischemic Cardiomyopathy Treatment Evaluation Trial
(DEFINITE), will address the utility of prophylactic ICD
therapy in the subset of patients with dilated cardiomyopa-
thy and non-ischemic heart failure. The counterpart of
DEFINITE for patients with coronary artery disease is the
MADIT II trial, in which patients are randomized to either
ICD or no anti-arrhythmic drug therapy. The Sudden
Cardiac Death in Heart Failure Trial (SCD-HeFT) is the
first heart failure trial focusing on prophylactic intervention
for sudden death. It is unique because its entry criteria are
based only on the presence of heart failure and low ejec-
tion fraction. Arrhythmia markers are not considered.
Patients with either ischemic or non-ischemic cardiomy-
opathy are included in this study. Although we have been
concerned that this study may not be powered sufficiently
to identify a small, but nevertheless, important improve-
ment in survival, we are optimistic, given the effectiveness
of the ICD, that a positive outcome favoring ICD therapy
will be forthcoming. Most of these ongoing trials included
an empiric ICD arm and incorporated maximal heart failure
therapy with ACE inhibitors and beta-blockers. At the con-
clusion of these trials, we should have a better under-
standing of which group of the high-risk patients will
benefit most from ICD therapy.
With the current transvenous lead systems, defibrillator
implantation can be now achieved with a brief (<24 h)
hospital stay, and is associated with less than 1% mortal-
ity and minimal morbidity risk. Defibrillators can additionally
provide sophisticated monitoring and diagnostic functions
that allow one to more accurately assess arrhythmia recur-
rence and determine the mode of death. Furthermore,
current generation devices are capable of providing a full
range of physiologic pacing, which can facilitate the
optimum utilization of beta-blocker therapy, potentially
resulting in even greater synergistic benefits on improving
survival. ICD therapy has also been shown to be cost-
effective in long-term management of patients with life-
threatening ventricular arrhythmias [26].
Conclusion
To summarize, patients with heart failure will undoubtedly
benefit from implantable defibrillators for prevention of
sudden death (Figure 2). Since the highest risk of arrhyth-
mia death occurs among patients with less severe func-
tional impairment (New York Heart Association class II–III),
defibrillator implantation should be considered early in the
course of illness. Empiric ICD therapy, targeting the popu-
lation with mild to moderate heart failure, will maximize the
impact of such therapy on improving long-term survival.
Our efforts should no longer be directed at trying to deter-
mine whether ICDs are effective in preventing sudden
death and improving survival in patients with heart failure.
We are confident that ICDs are effective, and believe the
outcomes of DEFINITE, MADIT II, and SCD-HeFT trials
will support this hypothesis. Our efforts should be re-
directed. First, we should be working with device manu-
facturers to reduce ICD costs and improve device
longevity to maximize cost-effectiveness of ICD therapy.
We should also optimize and standardize practice guide-
lines and troubleshooting strategies to guarantee safety
and effectiveness of ICD therapy. Finally, with the advent
of bi-ventricular and other newer modalities of pacing for
hemodynamic support, survival benefits may even be
extended to those with end-stage heart failure. We can
then focus on identifying the appropriate patient who will
experience the greatest improvement in heart failure symp-
toms and hemodynamic survival, because sudden death
will have been eradicated in this protected population.
Figure 2
Impacts of interventions on mortality.http://cvm.controlled-trials.com/content/1/2/098
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